Dr. Rüdiger Herrmann

• Advised a Swedish listed biotech company on the negotiation of an exclusive licence agreement regarding the development and commercialisation of its antibody product by a US company in China, Taiwan, Hong Kong and Macau.
• Advised a German listed biotech company on the global restructuring of its manufacturing and supply relationships, including the negotiation of a commercial manufacturing and supply agreement with its API supplier, as well as corresponding supply agreements with its third-party customers.^*
• Advised a German nutraceutical company on its corporate reorganisation, as well as on a global manufacturing and supply agreement with a US customer.
• Advised an Austrian listed biotech company on the negotiation of a clinical supply agreement with a global biopharma company ancillary to an existing collaboration and licence agreement.^*
• Advised a listed Polish biotec company on a global collaboration and licence agreement with a Dutch biotec partner. The agreement for the global development of fibrotic drugs included various collaboration and licensing aspects, as well as a right of first refusal for Galapagos. GDPR issues also needed to be specifically addressed.
• Advised an Austrian listed biotech company on a global licence agreement with a Swiss university.^*
• Advised a German cell therapy company on establishing an intra-group master services and supply agreement and other related agreements.^*
• Advised a Swiss biotech company on a collaboration and licence agreement with a Benelux biotech company involving the algorithm-based identification and selection of patient-individual tumour-specific drug targets.^*
• Advised a German listed biotech company on the negotiation of a global licence and co-development agreement for its lead compound and various ancillary agreements, including a development supply agreement and a manufacture licence and tech transfer agreement.^*
• Advised a Polish client on a global licence agreement with an Italian pharma company.
• Represented a German listed company in one of the first licence and global co-development deals between a Chinese pharma company and a Western company. The transaction included licensing and co-development aspects, as well as an equity component. Highly complex transaction regarding regulatory, financial and development arrangements.
• Advised a German biotech company on a licence and cooperation agreement with a world-leading diagnostics company.^*
• Advised a Polish biotec company on the launch of a joint venture subsidiary, which was co-financed by a European venture fund.^*
• Advised a listed European/US-based biotec company on an exclusive strategic collaboration with one of the leading US pharma companies.^*
• Advised a German biotec company on a licensing and co-development partnership for its lead compound with an Italian pharma company.^*
• Advised a German biotec company on a licensing and development partnership for a cancer compound with a Chinese biotec company.^*
• Advised a Dutch biotech company on a commercialisation agreement for gene therapy product and a co-development agreement with an Italian pharma company.^*
• Represented a Canada-based biotech company in a licence and equity investment transaction with a Chinese publicly listed company regarding the licensing of its platform technology for cardiovascular and metabolic diseases.^*
• Advised a leading German medical and pharmaceutical device company on its joint venture project in the Middle East and Russia.^*
• Advised a Germany-based animal health company on its joint venture and licence transaction with a China-based animal health company.^*
• Represented a listed German company in its cross-border licensing transaction with a China-based pharmaceutical company.^*

^* Matter handled prior to joining the firm.